论文部分内容阅读
为了探讨羟基喜树碱联合环磷酰胺+长春新碱+甲基强的松龙方案治疗难治或复发多发性骨髓瘤(MM)临床意义,对12例难治或复发MM患者实施羟基喜树碱联合方案化疗。羟基喜树碱(HCPT)6～8mg/(m2.d),d1～d5;环磷酰胺500mg/m2,d1;长春新碱0.5mg/d,d1～d4;甲基强的松龙1.0g,d1～d5;28d为1个周期。可评价10例患者中,8例(80%)病情获得不同程度的缓解,其中3例(37.5%)获得完全缓解(CR)和接近完全缓解(nCR),3例(37.5%)获部分缓解(PR),2例(25%)微小反应(MR);1例(10%)病情稳定(SD),1例(10%)病情进展(PD)。初步研究结果提示,HCPT联合方案是一个具有较好治疗前景的方案。
In order to investigate the clinical significance of hydroxycamptothecin combined with cyclophosphamide + vincristine + methylprednisolone treatment of refractory or recurrent multiple myeloma (MM), 12 patients with refractory or recurrent MM were treated with hydroxycamptothecin Alkaline combined chemotherapy. Hydroxycamptothecin (HCPT) 6-8mg / (m2.d), d1 ~ d5; cyclophosphamide 500mg / m2, d1; vincristine 0.5mg / d, d1 ~ d4; methyl prednisolone 1.0g , d1 ~ d5; 28d is one cycle. Of the 10 evaluable patients, 8 (80%) had varying degrees of remission and 3 (37.5%) had complete remission (CR) and nearly complete remission (nCR), and 3 (PR), 2 cases (25%) micro-reaction (MR), 1 case (10%) stable disease (SD) and 1 case (10%) disease progression (PD). Preliminary results suggest that HCPT is a combination of programs with better prospects for treatment.